NASDAQ:ESPR Esperion Therapeutics - ESPR Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Esperion Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $5.96 +0.14 (+2.41%) (As of 02/7/2023 10:28 AM ET) Add Compare Share Share Today's Range$5.72▼$5.9650-Day Range$5.09▼$7.4952-Week Range$3.28▼$8.87Volume169,381 shsAverage Volume1.45 million shsMarket Capitalization$439.13 millionP/E RatioN/ADividend YieldN/APrice Target$11.20 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Esperion Therapeutics MarketRank™ ForecastAnalyst RatingHold2.00 Rating ScoreUpside/Downside92.4% Upside$11.20 Price TargetShort InterestN/ADividend StrengthN/ASustainability-2.76Upright™ Environmental ScoreNews Sentiment0.18Based on 2 Articles This WeekInsider TradingSelling Shares$52,754 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($3.65) to ($1.98) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.11 out of 5 starsMedical Sector373rd out of 1,027 stocksPharmaceutical Preparations Industry187th out of 500 stocks 3.0 Analyst's Opinion Consensus RatingEsperion Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 2 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $11.20, Esperion Therapeutics has a forecasted upside of 92.4% from its current price of $5.82.Amount of Analyst CoverageEsperion Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for ESPR. Previous Next 0.0 Dividend Strength Dividend YieldEsperion Therapeutics does not currently pay a dividend.Dividend GrowthEsperion Therapeutics does not have a long track record of dividend growth. Previous Next 3.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreEsperion Therapeutics has received a 53.54% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Ezetimibe", "Clinical research services for pulmonary hearth diseases", and "Bempedoic acid" products. See details.Environmental SustainabilityThe Environmental Impact score for Esperion Therapeutics is -2.76. Previous Next 2.3 News and Social Media Coverage News SentimentEsperion Therapeutics has a news sentiment score of 0.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Esperion Therapeutics this week, compared to 2 articles on an average week.Search Interest14 people have searched for ESPR on MarketBeat in the last 30 days. This is an increase of 56% compared to the previous 30 days.MarketBeat Follows2 people have added Esperion Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Esperion Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $52,754.00 in company stock.Percentage Held by InsidersOnly 3.30% of the stock of Esperion Therapeutics is held by insiders.Percentage Held by Institutions85.87% of the stock of Esperion Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Esperion Therapeutics are expected to grow in the coming year, from ($3.65) to ($1.98) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Esperion Therapeutics is -1.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Esperion Therapeutics is -1.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About Esperion Therapeutics (NASDAQ:ESPR) StockEsperion Therapeutics, Inc. is a pharmaceutical company. It engages in the development and commercialization of oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol. The firm offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI.Read More Receive ESPR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Esperion Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ESPR Stock News HeadlinesFebruary 7, 2023 | finance.yahoo.comEsperion to Report Fourth Quarter and Full Year 2022 Financial Results February 21, 2023February 6, 2023 | americanbankingnews.comEsperion Therapeutics (NASDAQ:ESPR) Upgraded at Morgan StanleyFebruary 7, 2023 | Wall Street Watch Dogs (Ad)A gold storm is coming…“We are in the early stages of a mania – the calm before the storm.”...January 30, 2023 | finance.yahoo.comThe past five years for Esperion Therapeutics (NASDAQ:ESPR) investors has not been profitableJanuary 29, 2023 | americanbankingnews.comEsperion Therapeutics, Inc. (NASDAQ:ESPR) Receives $11.20 Average PT from BrokeragesJanuary 11, 2023 | benzinga.comRFK Announces Team-Wide Partnership with Esperion Therapeutics; Includes Primary Partnership for Brad Keselowski at the '23 Daytona 500January 11, 2023 | finance.yahoo.comRFK Announces Team-Wide Partnership with Esperion Therapeutics; Includes Primary Partnership for Brad Keselowski at the ’23 Daytona 500January 10, 2023 | markets.businessinsider.comH.C. Wainwright Reaffirms Their Buy Rating on Esperion (ESPR)February 7, 2023 | Wall Street Watch Dogs (Ad)A gold storm is coming…“We are in the early stages of a mania – the calm before the storm.”...January 10, 2023 | finance.yahoo.comPTC Therapeutics (PTCT) Soars 5.8%: Is Further Upside Left in the Stock?January 8, 2023 | finance.yahoo.comEsperion Outlines Upcoming Milestones and Announces Preliminary Fourth Quarter 2022 Financial ResultsJanuary 2, 2023 | thestreet.comEsperion (ESPR) Stock Hits Another 52-Week High TodayDecember 19, 2022 | finance.yahoo.comCLEAR Outcomes Accepted as Late-Breaking Clinical Trial at ACC.23 Annual Scientific Session & Expo together with the World Congress of Cardiology (ACC.23/WCC)December 13, 2022 | finance.yahoo.comEsperion to Participate in January Investor MeetingsDecember 8, 2022 | finance.yahoo.comIs Esperion Therapeutics (ESPR) Outperforming Other Medical Stocks This Year?December 8, 2022 | finance.yahoo.comEsperion (ESPR) Reports Positive Data From CLEAR StudyDecember 7, 2022 | finance.yahoo.comEsperion Therapeutics Reports Sooner Than Expected Positive Data From Nexletol TrialDecember 1, 2022 | finance.yahoo.comWhy Is Esperion Therapeutics (ESPR) Down 16.7% Since Last Earnings Report?November 24, 2022 | finance.yahoo.comXeris (XERS), Horizon to Develop Ready-to-Use TeprotumumabNovember 21, 2022 | finance.yahoo.comEsperion Therapeutics, Inc.'s (NASDAQ:ESPR) latest 9.4% decline adds to one-year losses, institutional investors may consider drastic measuresNovember 16, 2022 | finance.yahoo.comEsperion Appoints Ben Halladay Chief Financial OfficerNovember 16, 2022 | seekingalpha.comEsperion Therapeutics: Q3 Earnings Reveal Progress Ahead Of CLEAR Outcomes DataNovember 9, 2022 | finance.yahoo.comEsperion Virtual Research & Development Day to Highlight Pipeline Programs and Scientific FocusNovember 4, 2022 | finance.yahoo.comWall Street Analysts Think Esperion Therapeutics (ESPR) Could Surge 32%: Read This Before Placing a BetNovember 1, 2022 | finanznachrichten.deEsperion Therapeutics, Inc.: Esperion Reports Third Quarter 2022 Financial Results and Provides Company UpdateNovember 1, 2022 | msn.comRecap: Esperion Therapeutics Q3 EarningsNovember 1, 2022 | finance.yahoo.comEsperion Therapeutics (ESPR) Reports Q3 Loss, Misses Revenue EstimatesSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ESPR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Esperion Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ESPR Company Calendar Last Earnings11/02/2021Today2/07/2023Next Earnings (Estimated)2/28/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ESPR CUSIPN/A CIK1434868 Webwww.esperion.com Phone(734) 887-3903FaxN/AEmployees218Year FoundedN/APrice Target and Rating Average Stock Price Forecast$11.20 High Stock Price Forecast$22.00 Low Stock Price Forecast$6.00 Forecasted Upside/Downside+87.9%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($4.56) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-269,110,000.00 Net Margins-337.63% Pretax Margin-337.63% Return on EquityN/A Return on Assets-72.56% Debt Debt-to-Equity RatioN/A Current Ratio3.18 Quick Ratio2.82 Sales & Book Value Annual Sales$78.45 million Price / Sales5.60 Cash FlowN/A Price / Cash FlowN/A Book Value($3.23) per share Price / Book-1.85Miscellaneous Outstanding Shares73,680,000Free Float71,252,000Market Cap$439.13 million OptionableOptionable Beta0.21 Key ExecutivesSheldon L. KoenigPresident, Chief Executive Officer & DirectorBenjamin HalladayChief Financial OfficerKen FiorelliChief Technical Operations OfficerJoAnne Micale FoodyChief Medical OfficerWilliam J. SasielaSenior Vice President-Clinical DevelopmentKey CompetitorsKezar Life SciencesNASDAQ:KZRVeruNASDAQ:VERUGH ResearchNASDAQ:GHRSSilence TherapeuticsNASDAQ:SLNPhathom PharmaceuticalsNASDAQ:PHATView All CompetitorsInsiders & InstitutionsDaiwa Securities Group Inc.Sold 25,700 shares on 2/6/2023Ownership: 0.053%Simplex Trading LLCBought 324,500 shares on 2/2/2023Ownership: 0.000%SG Americas Securities LLCSold 66,920 shares on 2/2/2023Ownership: 0.022%ProShare Advisors LLCBought 2,643 shares on 2/2/2023Ownership: 0.021%Resources Investment Advisors LLC.Sold 14,000 shares on 2/2/2023Ownership: 0.015%View All Insider TransactionsView All Institutional Transactions ESPR Stock - Frequently Asked Questions Should I buy or sell Esperion Therapeutics stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Esperion Therapeutics in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" ESPR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ESPR, but not buy additional shares or sell existing shares. View ESPR analyst ratings or view top-rated stocks. What is Esperion Therapeutics' stock price forecast for 2023? 4 equities research analysts have issued twelve-month price targets for Esperion Therapeutics' stock. Their ESPR share price forecasts range from $6.00 to $22.00. On average, they predict the company's stock price to reach $11.20 in the next twelve months. This suggests a possible upside of 92.4% from the stock's current price. View analysts price targets for ESPR or view top-rated stocks among Wall Street analysts. How have ESPR shares performed in 2023? Esperion Therapeutics' stock was trading at $6.23 at the beginning of the year. Since then, ESPR stock has decreased by 6.6% and is now trading at $5.82. View the best growth stocks for 2023 here. When is Esperion Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 28th 2023. View our ESPR earnings forecast. How were Esperion Therapeutics' earnings last quarter? Esperion Therapeutics, Inc. (NASDAQ:ESPR) announced its quarterly earnings data on Tuesday, November, 2nd. The biopharmaceutical company reported ($2.62) earnings per share for the quarter, topping analysts' consensus estimates of ($2.86) by $0.24. The biopharmaceutical company earned $14.41 million during the quarter, compared to analyst estimates of $12.31 million. During the same quarter last year, the business posted ($3.07) EPS. What is Tim Mayleben's approval rating as Esperion Therapeutics' CEO? 20 employees have rated Esperion Therapeutics Chief Executive Officer Tim Mayleben on Glassdoor.com. Tim Mayleben has an approval rating of 80% among the company's employees. What other stocks do shareholders of Esperion Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Esperion Therapeutics investors own include ALDW (ALDW), Targa Resources (TRGP), Navios Maritime Partners (NMM), NVIDIA (nvda), Micron Technology (MU), SFL (SFL), Gilead Sciences (GILD), Boeing (BA), Alibaba Group (BABA) and BioMarin Pharmaceutical (bmrn). What is Esperion Therapeutics' stock symbol? Esperion Therapeutics trades on the NASDAQ under the ticker symbol "ESPR." Who are Esperion Therapeutics' major shareholders? Esperion Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Monaco Asset Management SAM (0.64%), Simplex Trading LLC (0.00%), Pinnacle Associates Ltd. (0.33%), Pinnacle Associates Ltd. (0.32%), Wolverine Asset Management LLC (0.12%) and Daiwa Securities Group Inc. (0.05%). Insiders that own company stock include Benjamin Looker, Eric Warren, Joanne M Foody, Sheldon L Koenig, Target N V Biotech and Timothy M Mayleben. View institutional ownership trends. How do I buy shares of Esperion Therapeutics? Shares of ESPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Esperion Therapeutics' stock price today? One share of ESPR stock can currently be purchased for approximately $5.82. How much money does Esperion Therapeutics make? Esperion Therapeutics (NASDAQ:ESPR) has a market capitalization of $428.82 million and generates $78.45 million in revenue each year. The biopharmaceutical company earns $-269,110,000.00 in net income (profit) each year or ($4.56) on an earnings per share basis. How many employees does Esperion Therapeutics have? The company employs 218 workers across the globe. How can I contact Esperion Therapeutics? Esperion Therapeutics' mailing address is 3891 RANCHERO DRIVE SUITE 150, ANN ARBOR MI, 48108. The official website for the company is www.esperion.com. The biopharmaceutical company can be reached via phone at (734) 887-3903 or via email at ir@esperion.com. This page (NASDAQ:ESPR) was last updated on 2/7/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.